BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36185179)

  • 1. Clinical features and outcomes of patients with follicular lymphoma: A real-world study of 926 patients in China.
    Gao F; Zhang T; Liu X; Qu Z; Liu X; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; Wang X; Zhang H
    Front Oncol; 2022; 12():863021. PubMed ID: 36185179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical features and outcomes of newly diagnosed follicular lymphoma concurrent with diffuse large B-cell lymphoma component].
    Lin ZJ; Zha J; Yi SH; Li ZF; Ping LY; He XH; Yu HF; Zheng Z; Xu W; Chen FL; Xie Y; Chen BY; Zhang HL; Wang L; Ding KY; Li WY; Yang HY; Zhao WL; Qiu LG; Li ZM; Song YQ; Xu B
    Zhonghua Xue Ye Xue Za Zhi; 2022 Jun; 43(6):456-462. PubMed ID: 35968587
    [No Abstract]   [Full Text] [Related]  

  • 3. Rituximab and Chemotherapy for Newly Diagnosed Follicular Lymphoma: Real-World Report of Polish Lymphoma Research Group.
    Paszkiewicz-Kozik E; Debowska M; Jakacka N; Kotarska M; Szymanski M; Wisniewski K; Konska A; Jarzembowska M; Drozd-Sokolowska J; Romejko-Jarosinska J; Szumera-Cieckiewicz A; Rymkiewicz G; Ziarkiewicz-Wroblewska B; Lech-Maranda E; Walewski J; Hus I
    Chemotherapy; 2022; 67(4):201-210. PubMed ID: 35249035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical Features of Diffuse Large B-Cell Lymphoma Transformed from Follicular Lymphoma].
    Zhang XL; Yu WJ; Zhu YN; Yang CM; Xiao F; Mai WY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1772-1778. PubMed ID: 36476902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of different staging systems and prognostic analysis of 110 primary gastrointestinal diffuse large B cell lymphoma].
    Mao L; Wang X; Wang CY; Xia B; Ning QY; Yang HL; Yu Y; Zhang YZ
    Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(24):1853-1858. PubMed ID: 31269579
    [No Abstract]   [Full Text] [Related]  

  • 6. Screening of Adverse Prognostic Factors and Construction of Prognostic Index in Previously Untreated Concurrent Follicular Lymphoma and Diffuse Large B-Cell Lymphoma.
    Qu Z; Zhang T; Gao F; Gong W; Cui Y; Qiu L; Qian Z; Zhou S; Meng B; Ren X; Li L; Wang X; Zhang H
    Biomed Res Int; 2022; 2022():4379556. PubMed ID: 35655476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early progression in follicular lymphoma in the absence of histological transformation or high-risk Follicular Lymphoma International Prognostic Index still has a favourable outcome.
    Muntañola A; Mozas P; Mercadal S; Huguet M; Bobillo S; Bastos-Oreiro M; Jiménez-Ubieto A; Rovira J; Rivero A; Tolosa C; Luizaga L; de Villambrosia SG; Novelli S; Caballero D; Salar A; Alonso-Álvarez S; Magnano L; Gutiérrez NC; Sancho JM; López-Guillermo A;
    Br J Haematol; 2023 Feb; 200(3):306-314. PubMed ID: 36261137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical characteristics and prognosis of patients with co-existing follicular lymphoma and diffuse large B-cell lymphoma components in rituximab era.
    Chen Y; Luo L; Chen L; Zheng X; Yang X; Zheng Z; Zheng J; Liu T; Yang T; Hu J
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2311-2318. PubMed ID: 36219261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Follicular lymphoma: first - line selection criteria of treatment].
    Nesterova ES; Kravchenko SK; Kovrigina AM; Gemdzhian EG; Plastinina LV; Babaeva FE; Obukhova TN; Magomedova AU; Gaponova TV; Kremenetskaya AM; Vorobyev AI
    Ter Arkh; 2019 Aug; 91(8):75-83. PubMed ID: 32598757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy.
    Mir F; Mattiello F; Grigg A; Herold M; Hiddemann W; Marcus R; Seymour JF; Bolen CR; Knapp A; Nielsen T; Casulo C
    Am J Hematol; 2020 Dec; 95(12):1503-1510. PubMed ID: 32815559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical features and outcomes of 1845 patients with follicular lymphoma: a real-world multicenter experience in China.
    Zha J; Fan L; Yi S; Yu H; Zheng Z; Xu W; Deng M; Lin Z; Li Z; Ping L; He X; Chen F; Xie Y; Chen B; Zhang H; Wang L; Ding K; Li W; Yang H; Zhao W; Qiu L; Li Z; Song Y; Xu B
    J Hematol Oncol; 2021 Aug; 14(1):131. PubMed ID: 34425858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical Features, Treatment and Prognostic Factors of 94 Patients with Follicular Lymphoma].
    DU XY; Hu K; Zhao W; Yang P; Wan W; Jing HM; Ke XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):756-764. PubMed ID: 29950216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life.
    Sortais C; Lok A; Tessoulin B; Gastinne T; Mahé B; Dubruille V; Blin N; Touzeau C; Moreau A; Bossard C; Peterlin P; Garnier A; Guillaume T; Le Bourgeois A; Chevallier P; Moreau P; Leux C; Le Gouill S
    Ann Hematol; 2020 Jul; 99(7):1595-1604. PubMed ID: 32417940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
    Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
    Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety-related factors of BTK inhibitors as a bridge to CAR-T therapy in R/R FL.
    Ye X; Fan X; Cui R; Mu J; Liu M; Lyu C; Li Y; Chen L; Zhang J; Li X; Wang J; Mou N; Deng Q
    Ann Hematol; 2023 Jul; 102(7):1789-1799. PubMed ID: 37171599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of outcomes after allogeneic hematopoietic stem cell transplantation in patients with follicular lymphoma, diffuse large B-cell lymphoma associated with follicular lymphoma, or de novo diffuse large B-cell lymphoma.
    Tada K; Kim SW; Asakura Y; Hiramoto N; Yakushijin K; Kurosawa S; Tajima K; Mori S; Heike Y; Tanosaki R; Maeshima AM; Taniguchi H; Furuta K; Kagami Y; Matsuno Y; Tobinai K; Takaue Y; Fukuda T
    Am J Hematol; 2012 Aug; 87(8):770-5. PubMed ID: 22641292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303.
    Russler-Germain DA; Krysiak K; Ramirez C; Mosior M; Watkins MP; Gomez F; Skidmore ZL; Trani L; Gao F; Geyer S; Cashen AF; Mehta-Shah N; Kahl BS; Bartlett NL; Alderuccio JP; Lossos IS; Ondrejka SL; Hsi ED; Martin P; Leonard JP; Griffith M; Griffith OL; Fehniger TA
    Blood Adv; 2023 Sep; 7(18):5524-5539. PubMed ID: 37493986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Follicular non-Hodgkin's lymphoma: correlation between histology, pathophysiology, cytogenetic, prognostic factors, treatment, survival.
    Găman AM
    Rom J Morphol Embryol; 2013; 54(1):71-6. PubMed ID: 23529311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of transformation on the survival of patients diagnosed with follicular lymphoma that progressed within 24 months.
    Yoon SE; Cho J; Kim WS; Kim SJ
    J Cancer; 2021; 12(9):2488-2497. PubMed ID: 33854610
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center.
    Huang H; Fan L; Fu D; Lin Q; Shen J
    Ann Palliat Med; 2020 Jul; 9(4):1442-1452. PubMed ID: 32648457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.